{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:35:15Z","timestamp":1784248515814,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.iac.2026.01.005","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:32:14Z","timestamp":1772627534000},"page":"291-303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beta-Blockers, Angiotensin-Converting Enzyme Inhibitors, and Anaphylaxis"],"prefix":"10.1016","volume":"46","author":[{"given":"Anne K.","family":"Ellis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Linton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.iac.2026.01.005_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.anai.2010.01.023","article-title":"World allergy organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings","volume":"104","author":"Simons","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.iac.2026.01.005_bib2","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jaci.2003.12.591","article-title":"Revised nomenclature for allergy for global use: report of the nomenclature review committee of the world allergy organization, October 2003","volume":"113","author":"Johansson","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.005_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2014Second national institute of allergy and infectious disease\/food allergy and anaphylaxis network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2026.01.005_bib4","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1081-1206(10)61086-1","article-title":"Epidemiology of anaphylaxis: findings of the American college of allergy, asthma and immunology epidemiology of anaphylaxis working group","volume":"97","author":"Lieberman","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"10.1016\/j.iac.2026.01.005_bib5","article-title":"World allergy organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ J [Internet]"},{"issue":"2","key":"10.1016\/j.iac.2026.01.005_bib6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","article-title":"Anaphylaxis: a 2023 practice parameter update","volume":"132","author":"Golden","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1016\/j.iac.2026.01.005_bib7","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.jaip.2023.04.037","article-title":"Refractory anaphylaxis: a new entity for severe anaphylaxis","volume":"11","author":"Pouessel","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.iac.2026.01.005_bib8","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/all.12638","article-title":"Clinical contraindications to allergen immunotherapy: an EAACI position paper","volume":"70","author":"Pitsios","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2026.01.005_bib9","author":"Gold"},{"issue":"2","key":"10.1016\/j.iac.2026.01.005_bib10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/all.15032","article-title":"EAACI guidelines: anaphylaxis (2021 update)","volume":"77","author":"Muraro","year":"2022","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.iac.2026.01.005_bib11","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jama.1984.03340350026019","article-title":"\u03b2-Blockade in stinging insect anaphylaxis","volume":"251","author":"Ingall","year":"1984","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.iac.2026.01.005_bib12","first-page":"48","article-title":"Insect sting anaphylaxis and beta-adrenergic blockade: a relative contraindication","volume":"53","author":"Awai","year":"1984","journal-title":"Ann Allergy"},{"issue":"1","key":"10.1016\/j.iac.2026.01.005_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0091-6749(88)90212-6","article-title":"Risk of anaphylaxis in patients receiving beta-blocker drugs","volume":"81","author":"Toogood","year":"1988","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.005_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0091-6749(81)90170-6","article-title":"Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade","volume":"68","author":"Jacobs","year":"1981","journal-title":"J Allergy Clin Immunol"},{"issue":"s14","key":"10.1016\/j.iac.2026.01.005_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1398-9995.1993.tb04754.x","article-title":"Position paper: immunotherapy","volume":"48","author":"Mailing","year":"1993","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.iac.2026.01.005_bib16","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaci.2009.08.027","article-title":"Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum Tryptase\u2014A study of the european academy of allergology and clinical immunology interest group on insect venom hypersensitivity","volume":"124","author":"Ru\u00ebff","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2026.01.005_bib17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaci.2004.11.012","article-title":"Use of \u03b2-blockers during immunotherapy for Hymenoptera venom allergy","volume":"115","author":"M\u00fcller","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.iac.2026.01.005_bib18","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1007\/s003300000778","article-title":"Contrast media safety committee of the european society of urogenital radiology. Prevention of generalized reactions to contrast media: a consensus report and guidelines","volume":"11","author":"Morcos","year":"2001","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.005_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.iac.2021.09.012","article-title":"Systemic allergic reactions and anaphylaxis associated with allergen immunotherapy","volume":"42","author":"Dhamija","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"10.1016\/j.iac.2026.01.005_bib20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jaci.2020.06.008","article-title":"Phenotype and risk factors of venom-induced anaphylaxis: a case-control study of the European anaphylaxis registry","volume":"147","author":"Francuzik","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.iac.2026.01.005_bib21","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1016\/j.jaip.2021.04.045","article-title":"Biomarkers of the severity of honeybee sting reactions and the severity and threshold of systemic adverse events during immunotherapy","volume":"9","author":"Kopa\u010d","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2026.01.005_bib22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.anai.2016.12.009","article-title":"Sublingual immunotherapy: a focused allergen immunotherapy practice parameter update","volume":"118","author":"Greenhawt","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1016\/j.iac.2026.01.005_bib23","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1111\/all.14785","article-title":"\u03b2-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy","volume":"76","author":"Sturm","year":"2021","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.iac.2026.01.005_bib24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/ACI.0000000000000657","article-title":"\u03b2-Blockers and angiotensin-converting enzyme inhibitors with sublingual immunotherapy: are risks related to individual product safety profile?","volume":"20","author":"Smith","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"8824","key":"10.1016\/j.iac.2026.01.005_bib25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/0140-6736(92)93314-D","article-title":"ACE inhibitors and anaphylactoid reactions during venom immunotherapy","volume":"340","author":"Tunon-de-Lara","year":"1992","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.iac.2026.01.005_bib26","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jaci.2012.03.024","article-title":"Over- and underestimated parameters in severe Hymenoptera venom\u2013induced anaphylaxis: cardiovascular medication and absence of urticaria\/angioedema","volume":"130","author":"Stoevesandt","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.005_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaci.2010.04.025","article-title":"Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase","volume":"126","author":"Ru\u00ebff","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.005_bib28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jaci.2020.06.008","article-title":"Phenotype and risk factors of venom-induced anaphylaxis: a case-control study of the european anaphylaxis registry","volume":"147","author":"Francuzik","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.005_bib29","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2010.09.034","article-title":"Allergen immunotherapy: a practice parameter third update","volume":"127","author":"Cox","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2026.01.005_bib30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.anai.2017.02.012","article-title":"Physicians\u2019 experience and opinion on contraindications to allergen immunotherapy: the CONSIT survey","volume":"118","author":"del Rio","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.iac.2026.01.005_bib31","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jaip.2017.12.020","article-title":"Patients taking \u03b2-blockers do not require increased doses of epinephrine for anaphylaxis","volume":"6","author":"White","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2026.01.005_bib32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jaip.2018.10.042","article-title":"Relationship between anaphylaxis and use of beta-blockers and angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis of observational studies","volume":"7","author":"Tejedor-Alonso","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2026.01.005_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13223-018-0282-5","article-title":"Allergen-specific immunotherapy","volume":"14","author":"Moote","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2026.01.005_bib34","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/01.mej.0000217993.09364.35","article-title":"Paradoxical reaction to epinephrine induced by beta-blockers in an anaphylactic shock induced by penicillin","volume":"13","author":"Goddet","year":"2006","journal-title":"Eur J Emerg Med"},{"issue":"4","key":"10.1016\/j.iac.2026.01.005_bib35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.5415\/apallergy.2012.2.4.280","article-title":"Biphasic anaphylaxis to gemifloxacin","volume":"2","author":"Yilmaz","year":"2012","journal-title":"Asia Pac Allergy"},{"issue":"3","key":"10.1016\/j.iac.2026.01.005_bib38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/08465371221083970","article-title":"Canadian association of radiologists guidance on contrast associated acute kidney injury","volume":"73","author":"Macdonald","year":"2022","journal-title":"Can Assoc Radiol J"},{"issue":"17","key":"10.1016\/j.iac.2026.01.005_bib39","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1001\/archinte.1993.00410170119012","article-title":"Elevated risk of anaphylactoid reaction from radiographic contrast media is associated with both \u00df-blocker exposure and cardiovascular disorders","volume":"153","author":"Lang","year":"1993","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.iac.2026.01.005_bib40","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.jaip.2019.10.020","article-title":"Risk for anaphylactic reaction from cardiac catheterization in patients receiving \u03b2-adrenergic blockers or angiotensin-converting enzyme-inhibitors","volume":"8","author":"Smith","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2026.01.005_bib41","series-title":"StatPearls [internet]","article-title":"Intravenous immunoglobulin (IVIG)","author":"Arumugham","year":"2025"},{"issue":"3","key":"10.1016\/j.iac.2026.01.005_bib42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/cei.13665","article-title":"Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study","volume":"206","author":"Martinez","year":"2021","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.iac.2026.01.005_bib43","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1536\/ihj.19-568","article-title":"Clinical characteristics, treatment, and outcomes in patients with idiopathic inflammatory myopathy concomitant with heart failure","volume":"61","author":"Liu","year":"2020","journal-title":"Int Heart J"},{"issue":"12","key":"10.1016\/j.iac.2026.01.005_bib44","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3889\/oamjms.2018.513","article-title":"Adverse reactions to intravenous immunoglobulins - our experience","volume":"6","author":"Kareva","year":"2018","journal-title":"Open Access Maced J Med Sci"},{"issue":"5","key":"10.1016\/j.iac.2026.01.005_bib45","first-page":"977","article-title":"Should \u03b2-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis","volume":"113","author":"TenBrook","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2026.01.005_bib46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/ACI.0000000000000539","article-title":"Therapeutic approach of anaphylaxis","volume":"19","author":"Tanno","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.005_bib47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/WOX.0b013e318211496c","article-title":"World allergy organization guidelines for the assessment and management of anaphylaxis","volume":"4","author":"Simons","year":"2011","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.iac.2026.01.005_bib48","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/j.bja.2019.04.044","article-title":"Management of suspected immediate perioperative allergic reactions: an international overview and consensus recommendations","volume":"123","author":"Garvey","year":"2019","journal-title":"Br J Anaesth"},{"issue":"7","key":"10.1016\/j.iac.2026.01.005_bib51","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/cea.14514","article-title":"Management of refractory anaphylaxis: an overview of current guidelines","volume":"54","author":"Pouessel","year":"2024","journal-title":"Clin Exp Allergy"},{"issue":"10","key":"10.1016\/j.iac.2026.01.005_bib49","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bjae.2019.06.002","article-title":"Perioperative anaphylaxis: pathophysiology, clinical presentation and management","volume":"19","author":"Dewachter","year":"2019","journal-title":"BJA Educ"},{"key":"10.1016\/j.iac.2026.01.005_bib50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40981-021-00490-4","article-title":"Successful treatment of severe adrenaline-resistant anaphylactic shock with glucagon in a patient taking a beta-blocker: a case report","volume":"7","author":"Murakami","year":"2021","journal-title":"JA Clin Rep"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856126000056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856126000056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:31:43Z","timestamp":1776349903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856126000056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0889856126000056"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2026.01.005","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-Blockers, Angiotensin-Converting Enzyme Inhibitors, and Anaphylaxis","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2026.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}